Citizens Jmp Raises GH Research (NASDAQ:GHRS) Price Target to $42.00

GH Research (NASDAQ:GHRS) had its price objective increased by equities research analysts at Citizens Jmp from $39.00 to $42.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s target price points to a potential upside of 163.65% from the company’s previous close.

Several other equities analysts also recently commented on GHRS. Weiss Ratings restated a “sell (d-)” rating on shares of GH Research in a research report on Thursday, January 22nd. Canaccord Genuity Group upped their price target on GH Research from $35.00 to $39.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Wolfe Research set a $39.00 price objective on GH Research in a report on Tuesday, January 6th. Needham & Company LLC boosted their target price on shares of GH Research from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Friday. Finally, HC Wainwright upped their target price on shares of GH Research from $35.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, GH Research presently has an average rating of “Moderate Buy” and an average price target of $39.50.

GH Research Stock Performance

NASDAQ:GHRS opened at $15.93 on Friday. The company has a 50-day moving average of $15.45 and a 200-day moving average of $14.25. GH Research has a 52 week low of $7.98 and a 52 week high of $19.51. The company has a market capitalization of $828.84 million, a price-to-earnings ratio of -19.91 and a beta of 1.00.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.06. Sell-side analysts forecast that GH Research will post -0.8 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GHRS. Barclays PLC boosted its stake in GH Research by 63.4% during the 4th quarter. Barclays PLC now owns 2,118 shares of the company’s stock worth $27,000 after purchasing an additional 822 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of GH Research in the fourth quarter worth about $38,000. Osaic Holdings Inc. boosted its position in GH Research by 63.6% during the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after acquiring an additional 2,400 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in GH Research during the second quarter worth about $79,000. Finally, Virtus Investment Advisers LLC purchased a new stake in GH Research during the 2nd quarter valued at about $89,000. Hedge funds and other institutional investors own 56.90% of the company’s stock.

Key Headlines Impacting GH Research

Here are the key news stories impacting GH Research this week:

• Positive Sentiment: Company business update — GH Research reported full‑year 2025 results and said it completed the Phase 2b GH001 trial in treatment‑resistant depression, presented the dataset at major conferences, and received FDA clearance to begin U.S. clinical investigations; the company also reported cash and marketable securities of $280.7M, which supports upcoming development programs. GH Research Reports Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Quarterly beat — GH Research reported EPS of ($0.23) vs. consensus ($0.29), surprising modestly to the upside, which likely helped lift sentiment. Quarterly press release
• Positive Sentiment: Analyst price‑target upgrades — Citizens JMP raised its target to $42 with a “market outperform” rating and Needham raised its target to $32 with a “buy” rating; separate coverage also shows a $70 target reported in the market press (HC Wainwright). These upgrades increase upside expectations and likely contributed to buying interest. Analyst upgrades (Benzinga) Needham PT raise Price target to $70 note
• Neutral Sentiment: Market commentary — Coverage noting GHRS activity across Nasdaq futures and broader market focus may amplify volatility but is not specific new corporate information. Kalkine Media article
• Neutral Sentiment: Short interest data appears non‑informative in recent reporting (shows 0 shares), so it does not appear to be a driver of current price action. (Reported days‑to‑cover is 0.0.)
• Negative Sentiment: HC Wainwright earnings revisions — Although HC Wainwright retains a “Buy” rating and a $70 target, the firm reduced near‑term EPS forecasts for FY2025–FY2028 (more negative near‑term EPS path), which introduces risk around timing and magnitude of commercialization and could temper upside. HC Wainwright comments

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.